Blocking the molecule MEK kept cancer-fighting T cells from burning out in lab and mouse studies
Memorial Sloan Kettering researchers found that the signaling molecule MEK drives T cells into exhaustion by making them overspend energy. Blocking it helped the cells persist in lab and animal models. MEK inhibitors are already approved drugs, but no patient has been tested yet.
By Diego Callegari, Editor
· United States · 3 min read
Source: Memorial Sloan Kettering Cancer Center ↗
Scientists at Memorial Sloan Kettering Cancer Center in New York have found that a signaling molecule called MEK drives cancer-fighting T cells into exhaustion, and that blocking it helped the cells keep going in laboratory and animal experiments, the center said. The study, from the lab of physician-scientist Santosha Vardhana, was published in the journal Immunity on 13 July.
No patient has received the treatment. Drugs that block MEK are already approved by the U.S. Food and Drug Administration for other uses, which the researchers say could speed up human testing.
Immunotherapy often fades when T cells tire out
Checkpoint inhibitors, one of the main forms of cancer immunotherapy, release a brake on T cells so they attack tumors. But under constant exposure to tumor proteins, T cells wear down and lose the ability to keep the cancer in check. Researchers call this T cell exhaustion.
“A tragic part of T cell exhaustion is that the immunotherapy seems to be working for patients, and then it fades.” — Santosha Vardhana, MD, PhD, physician-scientist, Memorial Sloan Kettering Cancer Center
Vardhana, who treats people with lymphoma, reported in 2020 that exhaustion starts with the cells' metabolism, the chemistry that turns nutrients into energy inside the mitochondria.
Exhausted cells were spending too much energy, not too little
The new work found that exhausted T cells were highly active metabolically. According to the paper's abstract, repeated stimulation of the cells' receptors raised their demand for ATP, the molecule cells use to store and move energy. That led to a buildup of reactive oxygen species and damage to the mitochondria.
MEK was the switch behind much of that demand. When it stayed active, the cells ramped up protein production across the board, including the toxic proteins they use to kill cancer cells. Of the signaling components the team tested, blocking MEK was the only one that reduced the cells' nutrient uptake and the mitochondrial buildup while restoring their ability to multiply. Treated cells divided more while using less energy, and in lab models they persisted even in the harsh conditions inside tumors.
"It changed how we think about T cell exhaustion," said first author Tanmana Mitra, a student in Vardhana's lab. The problem, she said, shifted "from a problem of too little energy to one of excessive energy demand."
A slower attack may suit patients with large tumors
Blocking MEK has a cost. It makes T cells more conservative, so they live longer but produce fewer of the proteins that kill cancer cells. Vardhana said that means it is probably not needed for patients who already respond well to immunotherapy, usually those with many immune cells attacking a tumor. It may help those with large tumors or few tumor-reactive T cells, where a slower, longer attack is needed.
MEK inhibition has already worked in melanoma when combined with checkpoint inhibitors and a targeted drug called a BRAF inhibitor, according to MSK. Vardhana said the approach could also help keep CAR T cells active longer, a known weakness of that therapy, and could be combined with tumor-infiltrating lymphocyte therapy and bispecific antibodies. Targeted cancer drugs are also moving into earlier treatment; in the United States, the FDA approved pirtobrutinib as a first treatment for chronic lymphocytic leukemia.
"FDA-approved MEK inhibitors are already available, so this approach could be tested in humans without much delay," he said. The release does not mention a planned trial.
Not medical advice. This article reports on research and health programs for general information. Results from early studies often change in larger trials. Talk to a doctor before making decisions about your own health or treatment.
Sources
- Memorial Sloan Kettering Cancer Center · mskcc.org
- doi.org
How we choose and verify sources: editorial policy.










